MycRx

Executive Summary

MycRx is a privately-held Australian biotech developing first-in-class small-molecule inhibitors targeting the Myc oncoprotein, a key driver of many solid tumors. The company's proprietary chemistry platform aims to create oral therapeutics that safely suppress Myc-driven tumor growth. Founded in 2020 and currently in preclinical stage, MycRx addresses a high-unmet need in oncology, as Myc dysregulation is prevalent in numerous cancers but historically considered 'undruggable'. With no disclosed funding or valuation, the company remains early-stage but benefits from a clear biological rationale and potential for broad applicability across multiple indications. The upcoming focus is on advancing lead candidates toward IND-enabling studies and securing Series A financing to support clinical translation.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement60% success
• H1 2027Lead Candidate IND Submission30% success
• Q4 2026Preclinical Efficacy Data Release70% success